Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/28246206http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/28246206http://www.w3.org/2000/01/rdf-schema#comment"

Lessons learned

The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group.The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma ABSTRACT: Background.The humanized IgG4 monoclonal antibody simtuzumab inhibits the extracellular matrix-remodeling enzyme lysyl oxidase-like 2 maintaining pathological stroma in tumors.

Methods

Adult patients with metastatic pancreatic adenocarcinoma (mPaCa) were randomly assigned to receive intravenous gemcitabine, 1,000 mg/m2, in combination with 200 or 700 mg simtuzumab or placebo. Primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.

Results

Of 240 patients, 80 were randomly assigned to gemcitabine/simtuzumab 700 mg, 79 to gemcitabine/simtuzumab 200 mg, and 81 to gemcitabine/placebo. After a median follow-up of 3.0, 1.9, and 3.4 months for gemcitabine/simtuzumab 700 mg, gemcitabine/simtuzumab 200 mg, and gemcitabine/placebo, respectively, the median PFS was 3.7 months (adjusted hazard ratio [HR], 95% confidence interval [CI], p value vs placebo: 1.09 [0.74-1.61]; p = .73), 3.5 months (1.13 [0.76-1.66], p = .61]), and 3.7 months, respectively. Median OS was 7.6 months (0.83 [0.57-1.22]; p = .28), 5.9 months (1.07 [0.73-1.55]; p = .69), and 5.7 months, respectively. ORRs were 13.9%, 14.5%, and 23.5%, respectively. Simtuzumab was well tolerated.

Conclusion

The addition of simtuzumab to gemcitabine did not improve clinical outcomes in patients with mPaCa. The Oncologist 2017;22:241-e7."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.org/dc/terms/identifier"doi:10.1634/theoncologist.2017-0024"xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/author"Dong H."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/author"Hecht J.R."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/author"Benson A.B."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/author"Wainberg Z.A."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/author"Bendell J."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/author"Kudrik F."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/author"Vyushkov D."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/date"2017"xsd:gYear
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/name"Oncologist"xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/pages"241-e15"xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/title"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma."xsd:string
http://purl.uniprot.org/citations/28246206http://purl.uniprot.org/core/volume"22"xsd:string
http://purl.uniprot.org/citations/28246206http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/28246206
http://purl.uniprot.org/citations/28246206http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/28246206
http://purl.uniprot.org/uniprot/#_B4DDQ4-mappedCitation-28246206http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28246206
http://purl.uniprot.org/uniprot/#_Q9Y4K0-mappedCitation-28246206http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28246206
http://purl.uniprot.org/uniprot/#_W6I206-mappedCitation-28246206http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28246206
http://purl.uniprot.org/uniprot/#_W8QRJ0-mappedCitation-28246206http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28246206
http://purl.uniprot.org/uniprot/W6I206http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/28246206
http://purl.uniprot.org/uniprot/W8QRJ0http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/28246206
http://purl.uniprot.org/uniprot/B4DDQ4http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/28246206
http://purl.uniprot.org/uniprot/Q9Y4K0http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/28246206
▶